|Bid||0.00 x 900|
|Ask||489.97 x 1100|
|Day's range||478.64 - 490.88|
|52-week range||362.90 - 505.00|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||46.31|
|Earnings date||22 Oct 2021|
|Forward dividend & yield||2.25 (0.46%)|
|Ex-dividend date||05 Oct 2021|
|1y target est||520.64|
The Roper Technologies Conference Call will now begin. Good morning, and thank you all for joining us as we discuss the third quarter financial results for Roper Technologies. Joining me on the call this morning are Neil Hunn, President and Chief Executive Officer; Rob Crisci, Executive Vice President and Chief Financial Officer; Jason Conley, Vice President and Chief Accounting Officer; and Shannon O'Callaghan, Vice President of Finance.
Roper's (ROP) Q3 earnings reflect improving segmental businesses, higher costs and expenses, and deleveraging actions. It also agrees to divest its CIVCO Radiotherapy business.
Roper Technologies (ROP) delivered earnings and revenue surprises of 1.30% and -9.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?